On May 16, 2025, Apimeds Pharmaceuticals US, Inc. granted significant equity awards to its top executives. The Chief Executive Officer received 750,000 shares of common stock and 347,279 stock options.
Additionally, the Chief Medical Officer was granted 250,000 shares of common stock. These grants are intended to strengthen the company's leadership team and incentivize key personnel.
The awards aim to align the interests of the executives with those of the shareholders, fostering long-term commitment and performance as Apimeds advances its Apitox development program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.